Skip to Content

Cromolyn (Nasal)



(KROE moe lin)

Index Terms

  • Cromoglicate
  • Cromoglycic Acid
  • Cromolyn Sodium
  • Disodium Cromoglycate
  • DSCG
  • Sodium Cromoglicate
  • Sodium Cromoglycate

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Aerosol Solution, Nasal, as sodium:

NasalCrom: 5.2 mg/actuation (13 mL, 26 mL) [contains benzalkonium chloride, edetate disodium]

Generic: 5.2 mg/actuation (26 mL)

Brand Names: U.S.

  • NasalCrom [OTC]

Pharmacologic Category

  • Mast Cell Stabilizer


Urine and feces (equal amounts as unchanged drug); exhaled gases (small amounts)

Onset of Action

Response to treatment: May occur at 1-2 weeks

Half-Life Elimination

80-90 minutes

Use: Labeled Indications

Prevention and treatment of seasonal and perennial allergic rhinitis


Hypersensitivity to cromolyn or any component of the formulation; acute asthma attacks

Dosing: Adult

Allergic rhinitis (treatment and prophylaxis): Intranasal: Instill 1 spray in each nostril 3-4 times/day; may be increased to 6 times/day (symptomatic relief may require 2-4 weeks)

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Allergic rhinitis (treatment and prophylaxis): Intranasal: Children ≥2 years: Refer to adult dosing.

Dosing: Renal Impairment

No dosage adjustment provided in manufacturer’s labeling.

Dosing: Hepatic Impairment

No dosage adjustment provided in manufacturer’s labeling.


Clear nasal passages by blowing nose prior to use.


Store at room temperature of 15°C to 30°C (59°F to 86°F). Protect from light.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

Frequency not defined.


Dermatologic: Burning sensation of the nose

Respiratory: Nasal mucosa irritation, sneezing, stinging sensation of the nose

1% to 10%:

Central nervous system: Headache

Gastrointestinal: Unpleasant taste

Respiratory: Cough, hoarseness, post-nasal drip

<1% (Limited to important or life-threatening): Epistaxis


Other warnings/precautions:

• Appropriate use: Prophylactic drug with no benefit for acute situations.

• Withdrawal: Caution should be used when withdrawing the drug or tapering the dose as symptoms may reoccur.

Pregnancy Considerations

Animal reproduction studies have not been conducted; however, studies in pregnant women have not shown signs of adverse effects or increased teratogenicity with use during pregnancy (Gilbert, 2005; Mazzotta, 1999).

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience sneezing, burning, or stinging. Have patient report immediately to prescriber severe nasal irritation (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.